跳至内容
Factliner

Novo Nordisk loses GLP-1 drug lead to Eli Lilly

Danish pharmaceutical giant Novo Nordisk saw its dominance in GLP-1 weight-loss drugs challenged by U.S. rival Eli Lilly after pioneering breakthrough treatments.

·1 min read·3 outlets

简要版本

Novo Nordisk, once Europe’s most valuable company, has lost its lead in the GLP-1 weight-loss drug market to U.S. rival Eli Lilly. The shift follows Novo Nordisk’s struggle to sustain momentum after pioneering obesity treatments.

Novo Nordisk briefly surpassed LVMH to become Europe’s most valuable company by market capitalization in 2023.3 The company’s share price rose due to strong sales of its weight-loss drugs Ozempic and Wegovy.3 Novo Nordisk pioneered GLP-1 treatments for obesity, which drove its market value.3

After its initial success, Novo Nordisk has struggled to develop follow-up blockbuster drugs.3 U.S. rival Eli Lilly outmaneuvered Novo Nordisk in the weight-loss drug market.2 Eli Lilly took control of the diet-drug market from Novo Nordisk.2

Employers, including Bank of America, face rising costs due to demand for GLP-1 drugs like Ozempic and Wegovy.1 GLP-1 drugs can cost thousands of dollars per patient annually.1

为何重要

  • GLP-1 drugs are a class of medications originally developed to treat type 2 diabetes but later approved for weight loss.3

  • Market capitalization measures a company’s total value by multiplying its share price by the number of shares outstanding.3

本文根据下列 3 篇报道撰写，来自 3 家独立媒体，并逐句核对。它不是其中任何一篇的复制。发现错误？ 告诉我们.

Well corroborated3 outlets
Left0Center3Right0

3 reports from 3 outlets. The numbers in the article point here.

Center3

Discussion

0

Comments are screened automatically. Disagreement is fine; abuse and spam are not.

Loading…

Related